Trials / Completed
CompletedNCT00297973
Cardiovascular Risk Assessment in Patients Treated With Caduet
Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors, Treated With Caduet Compared To Usual Care: The Right Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,442 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare the reduction in Framingham's predicted 10-year risk of a coronary event (6) in patients with hypertension and at least three other cardiovascular risk factors (including diabetic patients) seen in private practice and randomized to either Caduet or usual care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood pressure measurements | |
| PROCEDURE | Blood samples |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-04-01
- First posted
- 2006-03-01
- Last updated
- 2021-01-27
Locations
384 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00297973. Inclusion in this directory is not an endorsement.